Program overview
Context
Indication: Breast Cancer
Mechanism: Unknown
Modality: Unknown
Sponsor: Guangdong Provincial People's Hospital
Watchlist Signal
Tucidinostat (chidamide), PD-1 inhibitor (tislelizumab), anlotinib
Tucidinostat (chidamide), PD-1 inhibitor (tislelizumab), anlotinib is flagged as watchlist signal because public records show timeline staleness. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Scores
Risk-signal summary
Registry: 1/5
Timeline: 2/5
Recruitment burden: 1/5
Results availability: 0/5
Program risk: 2/5
Evidence
Public links
https://clinicaltrials.gov/study/NCT06547476
Linked trials
Trial-level signal details
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT06547476 | Low Signal (NOT_YET_RECRUITING) | stale_update_signal | long_recruitment_duration_signal | Low Signal | strict_eligibility_signal |